Rakovina Therapeutics Inc. (TSXV:RKV)

Market Cap	2.43M
Revenue (ttm)	n/a
Net Income (ttm)	-8.28M
Shares Out	21.15M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,034
Average Volume	43,255
Open	0.1200
Previous Close	0.1150
Day's Range	0.1150 - 0.1200
52-Week Range	0.0850 - 2.3000
Beta	-0.49
RSI	50.17
Earnings Date	Apr 28, 2026

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mads Daugaard
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RKV